Zúñiga-González S

Idioma: Español
Referencias bibliográficas: 28
Paginas: 217-221
Archivo PDF: 106.94 Kb.

RESUMEN

La deficiencia de hormona de crecimiento en el adulto (AO-GHD) es un diagnóstico pocas veces buscado. Esta deficiencia de hormona de crecimiento (GH) repercute en la calidad de vida del paciente, al causar cambios metabólicos, perfil adverso del riesgo cardiovascular, disminución de la densidad mineral ósea, alteraciones en la fuerza muscular, entre otros. Las causas principales de la AO-GHD son: enfermedades hipofisarias-hipotalámicas, irradiación o trauma craneal, hemorragia subaracnoidea, enfermedades infiltrativas y alteraciones genéticas. Entre los beneficios del tratamiento con GH en pacientes con hipopituitarismo, se encuentran: disminución de la adiposidad central, mejora del perfil de lípidos, disminución de citoquinas, y mejora en los marcadores de función endotelial y masa ventricular izquierda. El tratamiento con la hormona de crecimiento recombinante (GHr) en adulto, puede incrementar la glucosa dentro de los rangos normales, no provoca crecimiento en neoplasias de novo, o incremento en la velocidad de recrecimiento de tumores hipofisarios preexistentes. Los efectos secundarios dependen de la dosis y se presentan a dosis mayores. En el adulto mayor existe disminución progresiva de la producción de GH. La tendencia actual de sustitución con GHr, busca mejorar su calidad de vida, al proporcionarle beneficios como los arriba mencionados. El uso de dosis bajas de GHr, incluso en días alternos, proporciona al paciente sensación de bienestar y mejora en la circunferencia de cintura y el perfil de lípidos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 1992; 37(5): 387-397.

2. Hartman MI. The Growth Hormone Research Society consensus guidelines for the diagnosis and treatment of adult GH deficiency. Growth Horm IGF Res 1998; 8 (Suppl A): 25.

3. Carrol PV, Christer ER, Bengtsson BA, Carlson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorne M. Growth hormone deficiency in adultheod and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee, J Clin Endocrinol Metab 1998; 83: 382-395.

4. Nicolson A, Toogod AA, Rahim A, Shalet SM. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol (Oxf) 1996; 44: 311-316.

5. Toogood AA, Shalet SM. Diagnosis of severe growth hormone (GH) deficiency in young adults who received GH replacement therapy during childhood. Acta Paediatr Suppl 1997; 423: 117-120.

6. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wuster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999; 84: 3929-3945.

7. Colao A, di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001; 86: 1874-1881.

8. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 133(2): 111-122.

9. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. New Engl J Med 1999; 340: 14-22.

10. Smith JC, Evans Lm, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, Davies JS. Effect of GH replacement on endothelial function and large-artery stiffness in GH deficient adults: a randomized double-blind, placebo-controlled study. Clin Endocrinol (Oxf) 2002; 56: 493-502.

11. Colao A, di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001; 86: 1874-1881.

12. McConnell EM, Atkinson AB, Ennis C, Hadden DR, McCance DR, Sheridan B, Bell PM. The effects on insulin action in adult hypopituitarism of recombinant human GH therapy individually titrated for six months. J Clin Endocrinol Metab 2001; 86: 5342-5347.

13. Rusell-Jones DL, Watts GF, Weissberger A, Naoumova R, Myers J, Thompson GR, Sönksen PH. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Edocrinol (Oxf) 1994; 41: 345-350.

14. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003; 148(Suppl 2): S9-14

15. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, Johannsson G. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001; 86: 4657-4665.

16. Cummings DE, Merriam GR. Growth hormone therapy in adults. Annu Rev Med 2003; 54: 513-533.

17. Kannel WB, Cupples LA, Ramaswami R, Stokes J 3rd, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 1991; 44: 183-190

18. Proceedings of the 12th hGH Symposium. June 17-18, 2001. Keystone. Horm Res 2001; 56(Suppl 1): 1-6

19. Santos G, Frend K, Sensiom F, Terrentine R, Wills S. Growth hormone dose related side effects in HIV/AIDS population; retrospective study. Antiviral Therapy 2001; 6 (suppl 4): 73 (abstract 111 3rd Intern. Workshop on adverse drug reactions and lypodistrophy in HIV October 2001 Athens Greece).

20. Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996; 134: 352-356.

21. Petersenn S, Jung R, Beil FU. Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test. Eur J Endocrinol 2002; 146: 667-672.

22. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ; HyposCCS Advisory Board; U.S. HypoCCS Study Group. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002; 87: 477-485.

23. de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996;81:1371-1377.

24. Yuen K, Cook D, Ong K, Chatekain P, Fryklund L, GLuckman P, Ranke MB, Rosenfeld R, Dunger D. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults. Clin Endocrinol (Oxf) 2002; 57: 333-334.

25. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83: 379-381.

26. Papadakis MA, Grady D, Black D, Tierney MO, Gooding GA et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Int Med 1996; 124: 708-716.

27. Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson AG. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 2002; 87: 4900-4906.

28. Porias CH, Lamm WL. Análisis de la experiencia del uso de la hormona de crecimiento recombinante en adultos: beneficios y riesgos. Climaterio 2003; 35: 229-242.